Rapid itch relief after the first dose at Week 2, sustained at 1 year1,2
CHRONOS (18+ YEARS)
≥4-POINT REDUCTION IN PEAK PRURITUS NRS
(secondary endpoint)1,2,a-c
- At Week 16 in CHRONOS, 59% of adults treated with DUPIXENT + TCS (n=102) achieved a significant itch reduction vs 20% with placebo + TCS (n=299; secondary endpoint; P<0.0001)1,3,с
aIn the primary analyses of the efficacy endpoints, subjects who received rescue treatment or with missing data were considered nonresponders.1
bFull analysis set includes all subjects randomized.1
cIn CHRONOS, as needed, subjects received topical calcineurin inhibitors for problem areas only, such as the face, neck, and intertriginous and genital areas.1
dWeek 52 data were limited to patients completing 52 weeks as of the cutoff date.3
Significant itch reduction was also demonstrated with DUPIXENT in monotherapy trials (secondary endpoint)1,4
41%
of adults treated with DUPIXENT (n=213) achieved ≥4-point reduction in Peak Pruritus NRS vs 12% with placebo at Week 16 in SOLO 1 (n=212; P<0.001)
36%
of adults treated with DUPIXENT (n=225) achieved ≥4-point reduction in Peak Pruritus NRS vs 10% with placebo at Week 16 in SOLO 2 (n=221; P<0.001)
POST HOC ANALYSIS
Decrease in daily Peak Pruritus NRS from baseline in adults starting at Day 2 with DUPIXENT monotherapy5,a
Change in daily Peak Pruritus NRS from baseline in a post hoc analysis of pooled SOLO 1 and SOLO 2 trials (−4.5% with DUPIXENT [n=457] vs −0.6% with placebo [n=460]).
Definitive conclusions cannot be made as this was a post hoc analysis in which data were not multiplicity controlled and P value was nominal.
aPooled analysis of SOLO 1 and SOLO 2 (N=1379); ≥4-point improvement was seen at Day 4 in adult patients receiving Q2W dosing of DUPIXENT.
In DUPIXENT pivotal clinical trials in AD, itch was measured using a 0- to 10-point numerical rating scale (NRS) assessing a patient’s worst itch over the previous 24 hours.
To calculate6:
- Peak Pruritus NRS asks patients who can self-report (6+ years of age): "On a scale of 0 to 10, how would you rate your itch overall (on average) during the previous 24 hours?"
- Worst Scratch/Itch NRS asks caregivers of children aged 6 months to 5 years: "On a scale of 0 to 10, how would you rate the scratching/itching of the child you are a caregiver for at its worst during the previous 24 hours?"
imaginable
A reduction of ≥4 points from baseline is a clinically meaningful change.1
See itch relief data in other AD populations
Watch healthcare providers discuss itch relief with DUPIXENT
AD, atopic dermatitis; NRS, numeric rating scale; Q2W, every 2 weeks; TCS, topical corticosteroids.